Skip to main content

Research Repository

Advanced Search

Dr Joe Cuthbert's Outputs (10)

Heart rate reactivity, recovery, and endurance of the incremental shuttle walk test in patients prone to heart failure (2024)
Journal Article
Wei, F. F., Mariottoni, B., An, D. W., Pellicori, P., Yu, Y. L., Verdonschot, J. A., Liu, C., Ahmed, F. Z., Petutschnigg, J., Rossignol, P., Heymans, S., Cuthbert, J., Girerd, N., Li, Y., Clark, A. L., Nawrot, T. S., Ferreira, J. P., Zannad, F., Cleland, J. G., Staessen, J. A., & the HOMAGE investigators. (online). Heart rate reactivity, recovery, and endurance of the incremental shuttle walk test in patients prone to heart failure. ESC Heart Failure, https://doi.org/10.1002/ehf2.15000

Aims: Few randomized trials assessed the changes over time in the chronotropic heart rate (HR) reactivity (CHR), HR recovery (HRR) and exercise endurance (EE) in response to the incremental shuttle walk test (ISWT). We addressed this issue by analysi... Read More about Heart rate reactivity, recovery, and endurance of the incremental shuttle walk test in patients prone to heart failure.

Disease progression in chronic heart failure is linear: Insights from multistate modelling (2024)
Journal Article
Kazmi, S., Kambhampati, C., Rigby, A. S., Cleland, J. G. F., Kazmi, K. S., Cuthbert, J., Pellicori, P., & Clark, A. L. (online). Disease progression in chronic heart failure is linear: Insights from multistate modelling. European journal of heart failure, https://doi.org/10.1002/ejhf.3400

Aims: Understanding the pattern of disease progression in chronic heart failure (HF) may inform patient care and healthcare system design. We used a four-state Markov model to describe the disease trajectory of patients with HF. Methods and results:... Read More about Disease progression in chronic heart failure is linear: Insights from multistate modelling.

Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial (2024)
Journal Article
Yu, Y. L., Siwy, J., An, D. W., González, A., Hansen, T. W., Latosinska, A., Pellicori, P., Ravassa, S., Mariottoni, B., Verdonschot, J. A., Ahmed, F., Petutschnigg, J., Rossignol, P., Heymans, S., Cuthbert, J. J., Girerd, N., Clark, A. L., Verhamme, P., Nawrot, T. S., Janssens, S., …Collier, T. (in press). Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial. Heart, https://doi.org/10.1136/heartjnl-2023-323796

Objective Heart failure (HF) is characterised by collagen deposition. Urinary proteomic profiling (UPP) followed by peptide sequencing identifies parental proteins, for over 70% derived from collagens. This study aimed to refine understanding of the... Read More about Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial.

Outcomes in patients treated with loop diuretics without a diagnosis of heart failure: a retrospective cohort study (2024)
Journal Article
Cuthbert, J. J., Soyiri, I., Lomax, S. J., Turgoose, J., Fuat, A., Cohen, J., & Clark, A. L. (2024). Outcomes in patients treated with loop diuretics without a diagnosis of heart failure: a retrospective cohort study. Heart, 110(12), 854-862. https://doi.org/10.1136/heartjnl-2023-323577

Background Loop diuretics are commonly prescribed in the community, not always to patients with a recorded diagnosis of heart failure (HF). The rate of HF events in patients prescribed loop diuretics without a diagnosis of HF is unknown. Methods This... Read More about Outcomes in patients treated with loop diuretics without a diagnosis of heart failure: a retrospective cohort study.

Hospital admissions in the last year of life of patients with heart failure (2024)
Journal Article
AI Abel, A., Samuel, N. A., Cuthbert, J. J., Brown, O. I., Pellicori, P., Kazmi, S., GF Cleland, J., Johnson, M., & Clark, A. L. (2024). Hospital admissions in the last year of life of patients with heart failure. European Heart Journal - Quality of Care and Clinical Outcomes, 10(2), 168-175. https://doi.org/10.1093/ehjqcco/qcad047

Aim To explore the frequency, causes, and pattern of hospitalisation for patients with chronic heart failure (HF) in the 12 months preceding death. We also investigated cause of death. Methods Patients referred to a secondary care HF clinic were rout... Read More about Hospital admissions in the last year of life of patients with heart failure.

Diuretic Treatment in Patients with Heart Failure: Current Evidence and Future Directions-Part II: Combination Therapy (2024)
Journal Article
Cuthbert, J., Clark, A., & Cleland, J. (2024). Diuretic Treatment in Patients with Heart Failure: Current Evidence and Future Directions-Part II: Combination Therapy. Current Heart Failure Reports, https://doi.org/10.1007/s11897-024-00644-2

Purpose of Review Fluid retention or congestion is a major cause of symptoms, poor quality of life, and adverse outcome in patients with heart failure (HF). Despite advances in disease-modifying therapy, the mainstay of treatment for congestion loop... Read More about Diuretic Treatment in Patients with Heart Failure: Current Evidence and Future Directions-Part II: Combination Therapy.

Diuretic Treatment in Patients with Heart Failure: Current Evidence and Future Directions – Part I: Loop Diuretics (2024)
Journal Article
Cuthbert, J. J., & Clark, A. L. (2024). Diuretic Treatment in Patients with Heart Failure: Current Evidence and Future Directions – Part I: Loop Diuretics. Current Heart Failure Reports, 21(2), 101-114. https://doi.org/10.1007/s11897-024-00643-3

Purpose of Review: Fluid retention or congestion is a major cause of symptoms, poor quality of life, and adverse outcome in patients with heart failure (HF). Despite advances in disease-modifying therapy, the mainstay of treatment for congestion—loop... Read More about Diuretic Treatment in Patients with Heart Failure: Current Evidence and Future Directions – Part I: Loop Diuretics.

Medicines optimization prior to discharge in patients admitted to hospital with heart failure (2024)
Journal Article
Cuthbert, J. J., Brown, O. I., Pellicori, P., Dobbs, K., Bulemfu, J., Kazmi, S., Sokoreli, I., Pauws, S. C., Riistama, J. M., Cleland, J. G., & Clark, A. L. (2024). Medicines optimization prior to discharge in patients admitted to hospital with heart failure. ESC Heart Failure, 11(2), 950-961. https://doi.org/10.1002/ehf2.14638

Aims: Approximately half of patients with heart failure and a reduced ejection fraction (HeFREF) are discharged from hospital on triple therapy [angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs), beta-blockers... Read More about Medicines optimization prior to discharge in patients admitted to hospital with heart failure.

Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial (2024)
Journal Article
Wei, F. F., Pellicori, P., Ferreira, J. P., González, A., Mariottoni, B., An, D. W., Verdonschot, J. A., Liu, C., Ahmed, F. Z., Petutschnigg, J., Rossignol, P., Heymans, S., Cuthbert, J., Girerd, N., Clark, A. L., Li, Y., Nawrot, T. S., Díez, J., Zannad, F., Cleland, J. G., …Asayama, K. (2024). Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial. Hypertension Research, https://doi.org/10.1038/s41440-024-01843-z

None of the spironolactone trials in heart failure (HF) assessed the blood pressure (BP) responses to exercise, while conflicting results were reported for exercise capacity. In the HOMAGE trial, 527 patients at increased HF risk were randomized to u... Read More about Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial.